晚期非小细胞肺癌分子靶向药物研究新进展
New Advance of the Molecular Targeting Agents in AdvancedNon-small Cell Lung Cancer
摘要
分子靶向药物利用肿瘤细胞与正常细胞间分子生物学上的差异,抑制肿瘤细胞的生长增殖,最后使其死亡。本文介绍目前正在进行临床试验的几类分子靶向药物。
Molecule-targeting agents inhibit the proliferation of tumor cells by the molecular biological differ-ences between tumor cells and normal cells, and finally kill tumor cells. This article introduces several molecule-targeting agents that are currently under clinical trials now.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2004年第3期323-329,共7页
Acta Academiae Medicinae Sinicae
关键词
晚期非小细胞肺癌
分子靶向药物
advanced non-small cell lung cancer
molecular targeting agents
参考文献38
-
1Ranson M, Hammond L, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid,malignant tumors: Results of a phase Ⅰ trial. J Clin Oncol,2002, 20:2240-2250
-
2Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase Ⅰ trial. J
-
3Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (IDEAL 1). J Clin Oncol, 2003, 21:2237-2246
-
4Kris M, Natale RB, Herbst RS, et al. A phase Ⅱ trial of ZD1839 (‘Ir essa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol, 2002, 21:292a
-
5Miller VA, Shah N, Kris MG, et al. Clinical, pathologic,and molecular characteristics of NSCLC patients sensitive to gefitinib. Lung Cancer, 2003, 41(suppl 2):71
-
6Chiu CH, Tsai CM, Chiang SC, et al. Effect of ZD1839(Iressa) on metastatic brain lesions in patients with advanced non-small cell lung cancer. Lung Cancer, 2003, 41(suppl 2):251
-
7Giaccone G, Johnson DH, Manegold C, et al. A phase Ⅲ clinical trial of ZD1839 (‘Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1).Ann Oncol, 2002, 13(suppl 5):2
-
8Johnson Dh, Herbst R, Giaccone G, et al. ZD1839 (''Iressa'')in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): Results from a phase Ⅲ clinical trial (INTACT 2). Ann Oncol, 200
-
9Perez-Soler R, Chachoua A, Huberman M, et al. Final results from a phase Ⅱ study of Erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy.Lung Cancer, 2003, 41(suppl 2):246
-
10Kim ES, Mauer AM, Fossella FV, et al. A phase Ⅱ trial of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cance
-
1胡卫锋,李文洲,李运柱,陈琳,余家俊,彭松,李国灏,冯滔,张伟,郭枫.膀胱肿瘤术后膀胱灌注药物应用分析[J].药物流行病学杂志,2009,18(3):200-202.
-
2王忠革,王家玉.2003—2005年我院内分泌治疗乳腺癌药物利用分析[J].临床药物治疗杂志,2007,5(2):33-35.
-
3郭新平.切除子宫肌瘤的不同方法的临床观察[J].内蒙古医学杂志,2015,47(10):1229-1230.
-
4龙素华,陈国焱.西妥昔单抗在鼻咽癌治疗中的临床应用及护理[J].健康天地（学术版）,2010,4(3):54-54.
-
5孙佳良,尤君.癌痛患者使用麻醉性镇痛药品情况调查[J].中国误诊学杂志,2007,7(30):7378-7379. 被引量：6
-
6杨锐,赵晶,徐刚,丁曦,刘畅.癌痛麻醉药品药物利用调查分析[J].中国肿瘤临床与康复,2004,11(4):381-383. 被引量：2
-
7王芳,王金荣.吉林市医院2006年晚期癌痛麻醉性镇痛药应用调查[J].中国误诊学杂志,2007,7(25):6202-6203.
-
8潘碧云,虞和永.卵巢癌的化疗药物利用及成本分析[J].中国药学杂志,2005,40(7):559-560.
-
9张强,谢景文,贾正平,徐丽婷,张汝学.晚期癌症住院患者止痛药使用分析[J].药物流行病学杂志,2002,11(2):76-77. 被引量：2
-
10黄炬辉.纳米药物在肝癌靶向治疗中的临床研究[J].当代医学,2015,21(13):11-12.
